We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.00 | -0.12% | 1,638.50 | 1,638.00 | 1,639.00 | 1,647.00 | 1,634.00 | 1,638.50 | 701,416 | 12:53:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.65 | 67.29B |
Date | Subject | Author | Discuss |
---|---|---|---|
11/7/2019 09:20 | yes give him my regards...ho,ho, | lippy4 | |
11/7/2019 09:06 | could always buy a condolance card for Porsche ;) | stevieweebie2 | |
11/7/2019 08:52 | Received my dividends in my AJ Bell accounts today. When to reinvest the £8K in GSK, then? ….. ;0) | tradermichael | |
11/7/2019 07:57 | Brussels (AFP) - The EU on Wednesday approved the merger of the consumer healthcare activities of pharmaceutical giants GlaxoSmithKline and Pfizer that produce over-the-counter medicines. The European Commission, the EU's powerful anti-trust authority, said the decision came after the UK and US companies agreed to divest Pfizer's ThermaCare pain therapy brand. This commitment removes "almost entirely the overlaps between GSK and Pfizer's Consumer Health Business", the commission said. The greenlight is a crucial hurdle for the tie-up of over-the-counter brands with combined sales of 9.8 billion pounds ($12 billion, 11 billion euros) that include GSK's Sensodyne toothpaste and Pfizer's Centrum multivitamins. With the venture, British group GSK is split into two entities, one specialised in the development of drugs and the other in consumer healthcare. | tradermichael | |
10/7/2019 12:36 | Yes, £ v $ has fallen from 1.33 to 1.25 (6%) over past year. Strong new sales growth (e.g. Shingrix) coupled with Sterling's weakness look good for earnings and underpins the dividend ….. ;0) | tradermichael | |
10/7/2019 12:23 | TM, So earnings on the 5% upside? | beckers2008 | |
10/7/2019 12:13 | £1 = US$ 1.25 | tradermichael | |
10/7/2019 01:22 | Just noticed GSK has now taken over from TATE as my largest holding :-) | philanderer | |
09/7/2019 15:45 | yes 8 million cows killed when there was no reason,good old eu in action,i dont think.. love the share price that millionaire was so wrong about it dropping like a stone,hopefully this is the future.. divi day will be the main factor for the future. | lippy4 | |
09/7/2019 13:35 | G2 - don't tempt me!!! | alphorn | |
09/7/2019 12:23 | Mad Cow was tragic for farmers but wonderful for consumers. The shops could hardly give the stuff away so I ate more beef and steak then than at any other time before or since. Needless to say it did me no harm at all. | grahamite2 | |
09/7/2019 11:53 | soon to be put down though... | lippy4 | |
09/7/2019 09:32 | Nice one. ;) | alphorn | |
09/7/2019 09:19 | Too late Buywell. It's already in number 10 for starters. | crossing_the_rubicon | |
09/7/2019 06:50 | Worth watching IMO as Mad Cow cases (BSE) happened in Scotland last year, in Brazil a couple of months ago , and in Florida in Aug 2018.It has never gone away. 9:00pm on Thursday 11 July 2019 Mad Cow Disease: The Great British Beef Scandal – BBC2 › Episodes 7 days ago - The story of the outbreak of mad cow disease and its devastating effects are explored in BBC2's ... Airs at 9:00pm on Thursday 11 July 2019. | buywell3 | |
08/7/2019 17:25 | ViiV Healthcare launches U.S. study on implementation of monthly HIV treatment ViiV Healthcare commences a U.S.-based study, CUSTOMIZE, aimed at identifying and assessing the best ways to implement a once-monthly injectable treatment for HIV infection into clinical practice. The goal is to find the most practical and efficient ways to manage monthly treatment. In April, ViiV submitted its marketing application to the FDA seeking approval for its once-monthly two-drug HIV regimen of cabotegravir and Janssen's rilpivirine. The agency's action date under Priority Review status is December 29. ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (GSK -0.5%), Pfizer (PFE -1.3%) and Shionogi (OTCPK:SGIOY -3.1%). | crossing_the_rubicon | |
08/7/2019 15:31 | bazzerhino. Dividend due to be paid 11th july gsk due to go ex-div 8th of august at which time it could drop =/- the amount of the dividend (19p) which reduces the value of the company. To-days drop is just normal trading. Hope that helps. | sicker | |
08/7/2019 14:34 | I read somewhere that the share price usually drops on the day that dividends are paid. Is that what happens here? | bazzerhino | |
08/7/2019 11:53 | Yes please!!! | toffeeman | |
08/7/2019 09:41 | Cmon GSK back to 15.20, you know you can do it..... | porsche1945 | |
07/7/2019 10:39 | ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivu Authorisation based on GEMINI pivotal trials in which Dovato achieved non-inferior efficacy compared to a dolutegravir-based, three-drug regimen through 48 weeks, with no cases of resistance. | tradermichael | |
03/7/2019 20:55 | Very little resistance till £17 | tim 3 | |
03/7/2019 19:24 | Either the broker or the registrars and they will send you a bank mandate form to complete... Equiniti : 0371 384 2030... ZZZ | zorija |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions